Medical and automotive industries become the focus of anti-monopoly
The National Development and Reform Commission announced the first anti-monopoly ticket in the field of medical devices on the 7th. International giant Medtronic was fined 118.5 million yuan for the implementation of the price monopoly agreement. The reporter learned from law enforcement agencies that next year China's anti-monopoly work will focus on the people's livelihood industry represented by the medical industry. The anti-monopoly law enforcement of the automobile industry will be normalized, and the monopoly problem in the new business of automobile distribution will be thoroughly investigated. In addition, the decision on penalties for a multinational car company will be announced in the near future. It is understood that Medtronic sells medical device products in the domestic market in China, and its counterparts include platform vendors and first-tier dealers. According to law enforcement agencies, at least since 2014, Medtronic has reached a monopoly agreement with its counterparts through distribution agreements, email notifications, oral negotiations, etc., limiting the resale price, bid price and minimum sales to hospitals of related medical device products. The price, and through the formulation of the product price list of various distribution links, internal assessment, cancellation of dealers low-priced winning products and other measures, implemented a price monopoly agreement. Medtronic also adopted measures to vertically limit sales targets and sales areas and restrict the distribution of competitive brand products, further strengthening the implementation effect of the vertical price monopoly agreement. The National Development and Reform Commission announced that at present, the market competition for high-value consumables and implantable medical equipment in China is not sufficient, and manufacturers mainly adopt resale sales methods. Fair competition among dealers is to promote product competition and form a reasonable market price. An important aspect. Medtronic is an industry leader in cardiovascular, restorative therapy and diabetes-related medical devices. It strictly limits resale prices, eliminates and limits competition among dealers, limits competition among medical device brands, and maintains The high price of related medical device products hinders the normal functioning of the market price mechanism, increases the burden on patients, and harms the interests of consumers. The law enforcement agency imposed a fine of 4,85 million yuan on Medtronic's 4% sales of products involved in the year 2015. Xu Xinyu, director of the Anti-Monopoly Bureau of the National Development and Reform Commission, told the reporter of the Economic Information Daily that the law enforcement agencies in this case comprehensively considered the products covered by Medtronic’s illegal activities, the sales involved, the specific performance of price restrictions, and Medtronic’s investigation in the middle and later stages. Coordination and rectification, while taking into account the punishment of past cases, especially the scope of penalties for vertical monopoly cases, and finally determined the fines of 4% of the sales of the products involved. Zhang Handong, director of the Anti-Monopoly Bureau of the National Development and Reform Commission, said that in recent years, law enforcement agencies have paid close attention to the market competition order in the medical and health fields, and conducted in-depth research on monopoly, restrictions on competition, and high prices. Manufacturers strictly maintain resale prices and prohibit dealers from lowering prices, which is an important factor in the high price of related medical device products. Law enforcement agencies investigated and promulgated the case in accordance with the law. At the same time, Medtronic developed a comprehensive rectification measure, hoping to play the role of warning and guidance to further promote fair competition in the medical device industry and reduce the burden on patients. In the next step, we will continue to strengthen market competition supervision, seriously investigate and deal with monopolistic behaviors in accordance with the law, and promote the rational formation of medical device products. Lu Yanchun, deputy director of the Anti-monopoly Bureau of the National Development and Reform Commission, said that this case is the first monopoly case in the field of medical devices identified by the National Development and Reform Commission. The law enforcement agencies attached great importance to the investigation and handling of cases, not only conducted a comprehensive and in-depth investigation of the parties, but also organized a number of investigation teams to verify the prices of the resale links of the products involved, the facts of the case, the composition of the evidence chain, the impact of competition, etc. The issue has carried out in-depth and meticulous research and argumentation, and has been punished in strict accordance with the provisions of China's Anti-Monopoly Law. At the same time, it will also dynamically track and supervise the parties' rectification measures, further safeguarding fair competition and benefiting patients in the fields of cardiovascular and diabetes. 1.uncut sheet for urine test low price Uncut Sheet,Uncut Sheet Strips,Rapid Uncut Sheet,Uncut Sheet Urine Strips Changchun LYZ Technology Co., Ltd , https://www.lyzinstruments.com
2.uncut sheet for urine test high quality
3.uncut sheet for urine test rapidly
4.uncut sheet for urine test OEM design welcome
The benefit to purchase rapid uncut sheet for urine test strip :
To help you saving the shipping cost
To help you being the manufacture
To help you saving the import tax as the materials
Our factory can supply more than 30 kinds of rapid test sheets
Package: aluminum foil package
Advantage: vacuum package can protect the effect of moisture